Skip to main content Help with accessibility Skip to main navigation

Cannabis extract – Delta-9-Tetrahydrocannabinol (THC) 27mg and Cannabidiol (CBD) 25mg (Sativex®) oromucosal spray

Indication

For symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication.

This recommendation only covers the use of Delta-9-Tetrahydrocannabinol (THC) 27mg and Cannabidiol (CBD) 25mg (Sativex) oromucosal spray for the indication of moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication

Cannabis-based medicinal products NG144
Amber level 0

Brand:

Sativex®

Nice TA:

Commissioning responsibility:

CCG

PbR excluded:

No

BNF chapter:
Musculoskeletal system

Background

Recommendation

LSCMMG Recommendation:

Amber level 0

Reason for decision:

Suitable for GP prescribing following recommendation/initiation by specialist

Decisions of Lancashire local decision making groups

Amber 0
Amber 0
Amber 0
Amber 0
Amber 0
Amber 0
Amber 0
Amber 0
What do the colours mean?

Last Updated: 14 - Sep - 2021